KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular subset characterized by historical disappointments in targeted treatment approaches such as farnesyl transferase inhibition, downstream MEK inhibition, and synthetic lethality screens. Unlike other important mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Adderley, Helen, Blackhall, Fiona H., Lindsay, Colin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444074/
https://www.ncbi.nlm.nih.gov/pubmed/30852159
http://dx.doi.org/10.1016/j.ebiom.2019.02.049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444074/
https://www.ncbi.nlm.nih.gov/pubmed/30852159
http://dx.doi.org/10.1016/j.ebiom.2019.02.049

Ejemplares similares